



**Supplementary Fig. 1. Time course of MRI signal during CGRP infusion in rat brain.** **(a)** Time course of mean MRI signal change (black line) observed before, during (blue bar), and after 0.1  $\mu$ L/min infusion of 100 nM wtCGRP into rat thalamus. Signals were averaged over six animals in 1.5 mm square regions of interest (ROIs) positioned around the infusion cannulae tips in each animal (cf. Fig. 2d); gray shading denotes standard errors as a function of time. **(b)** Time courses from multiple approximately concentric ROIs (diagrammed at left) were analyzed to determine whether hemodynamic MRI has sufficient spatial resolution to monitor convection of CGRP from the infusion site. For each ROI, the delay between the start of infusion and the observation of statistically significant signal changes from baseline was measured (color coded bars at right). The onset of significant signal changes increases monotonically with distance from the cannula tip, consistent with the expected spread of the imaging agent during infusion. Times to significance observed in peripheral ROIs (green, brown, and purple) were all significantly longer than the time to significance observed for the innermost ROI (red, all pairwise  $t$ -tests  $p < 0.05$ ). Error bars denote SEM; all measurements  $n = 6$ .




**Supplementary Fig. 2. Cell-based bioassay for CGRP activity.** **(a)** Mechanism of vasodilation by CGRP. CGRP peptide binds and activates the heterodimeric CGRP receptor (RAMP1:CLR) on vascular smooth muscle cells (VSMCs). Activation of adenylate cyclase (AC) results in cyclic adenosine monophosphate (cAMP) production that acts through protein kinase A (PKA)-dependent and independent pathways to inhibit myosin light chain kinase (MLCK), resulting in VSMC relaxation and blood vessel dilation. **(b)** Engineered HEK293FT reporter cells provide a readout of cAMP accumulation upon activation of the CGRP receptor via a constitutively expressed, cAMP-responsive luciferase variant, Glo22F (Promega). **(c)** Lentiviral transgenes used to construct the CGRP reporter cell line. Full sequences provided in Supplementary Information.


**(d)** Fluorescence micrographs verifying expression of fluorescent reporters expressed by vectors encoding the Glo22F luciferase (C512) and the heterodimeric CGRP receptor components (C504 and C505) in cell lines transfected with constructs as noted at left. Color channels (labeled at top) depict bright field (BF) images, H2B-Cerulean (nuclear) with bleed-through from EYFP (cytosolic), EYFP alone, and mKate2. **(e-g)** Pharmacological validation of the reporter cell line, with error bars denoting SD of measurements performed in triplicate. **(e)** Dose-response curve for synthetic wild-type human alpha CGRP for reporter cell line infected with lentiviruses C504, C505, and C512 (blue) and for a cell line transfected with the cAMP reporter vector C512 but not the CGRP receptor vectors (gray). Luminescence values were normalized to the range evoked by buffer vs. 100  $\mu$ M forskolin for each cell line. **(f)** Dose-response curves for CGRP in absence or presence of different concentrations of the competitive inhibitor [8-37]CGRP, a C-terminal fragment of CGRP. Luminescence values were normalized to the range obtained with buffer vs. 100 nM CGRP. **(g)** Tabulated potencies for CGRP in the presence of different [8-37]CGRP concentrations. SEM values were all less than 0.1 ( $n = 7$ ).



**Supplementary Fig. 3. Impact of small terminal modifications on CGRP potency.** (a) Sequence of peptide variants. -NH<sub>2</sub> denotes an amidated C-terminus; CGRP-OH and CGRP-G contain a regular C-terminal carboxylate. Bioassays were performed with peptides serially diluted into water plus 0.1% CHAPS from 100 μM stock solutions in water or 50% DMSO. Error bars denote SD of measurements performed in triplicate. (b) Dose-response curves for C-terminally modified CGRP variants. Values normalized to the range obtained with buffer vs. 100 nM wtCGRP stimulation. (c) Dose-response curves for N-terminally modified CGRP variants. (d) Half maximal potencies, presented as log(EC<sub>50</sub>), determined from the dose-response data in panels b and c. Standard errors were all less than 0.1 ( $n = 7$ ).



**Supplementary Fig. 4. Proteolytic cleavage of candidate sensors and assessment by bioassay.** (a-e) Cleavage reaction products after incubation of 10  $\mu\text{M}$  sensor with or without enzyme for 2 h at 37 °C. (a) MALDI mass spectrum of sensor (1) after incubation with or without FAP shows near-complete cleavage and liberation of free CGRP. (b) SDS-PAGE analysis of sensor (2) after incubation with or without TEV protease shows substantial but not complete cleavage. (c) SDS-PAGE analysis of sensor (3) after incubation with different concentrations of EK light chain shows increasing cleavage with increasing concentrations. (d) SDS-PAGE analysis of sensor (4) after incubation with or without caspase-3 shows near-complete cleavage. (e) MALDI mass spectrum of sensor (5) after incubation with or without caspase-3 shows complete cleavage and liberation of free CGRP. (f-k) Dose-response curves of uncleaved and cleaved sensors in cell-based bioassay. All measurements were normalized to blank=0 and 100  $\mu\text{M}$  wtCGRP = 1.0. (f) Dose-response curves for Sensors (2-4) at final assay concentrations up to 10  $\mu\text{M}$  (addition of 10  $\mu\text{L}$  of 100  $\mu\text{M}$  solution to 90  $\mu\text{L}$  medium per well in bioassay) show no receptor activation by uncleaved GFP-linker-CGRP-G sensors even at 10-fold higher concentrations than were used in cleavage assays (g-k). (g-k) Dose-response curves for reaction products from (a-e). Error bars in (f-k) denote SD of measurements performed in triplicate.



**Supplementary Fig. 5. MRI and histological signals from injected control cells.** **(a)** Comparison of MRI (left) and optical microscopy (right) images of a field of view near injection of control HEK293FT cells in an individual animal, paralleling the data in main text Fig. 4e. The MRI scan shows no colored voxels overlaid on the grayscale anatomical image because MRI signal changes over 10% were not observed within a day of control cell implantation; this is in contrast to MRI results from CGRP-expressing cells in Fig. 4e. The histological image shows a bright field grayscale image, with mKate fluorescence in red overlaid to indicate the distribution of injected cells. Scale bar = 2 mm. **(b)** Close-ups of bright field images in the neighborhood of cell implantation on CGRP-expressing (left) and control cell (right) injection sites in a representative animal, showing normal patch-matrix striatal structural organization on both sides. The field of view corresponds to the rectangular box in panel a (right). Scale bar = 1 mm.

**Supplementary Table 1. Catalog of plasmids used in this study**

ID	Name	Source
Z503	pEXPR-T7-cfSGFP2-DEVD-CGRP-G	This study
Z507	pEXPR-T7-cfSGFP2-DDDDK-CGRP-G	This study
Z508	pEXPR-T7-cfSGFP2-ENLYFQG-CGRP-G	This study
C501	pLV-hEF1a-mKate-2A-bla	This study
C503	pLV-hEF1a-prepro-CGRP-IRES-mKate-2A-bla	This study
C504	pLV-hEF1a-myc-RAMP1-IRES-mKate-2A-bla	This study
C505	pLV-hEF1a-HA-CALCRL-IRES-EYFP-2A-Hygro	This study
C512	pLV-hEF1a-Glo22F-IRES-H2B-Cerulean-2A-puro	This study
X106	pMD2.G	Addgene 12259
X107	psPAX2	Addgene 12260
X108	pLenti X1 Zeo DEST (668-1)	Addgene 17299
X109	pEF-ENTR A (696-6)	Addgene 17427

**Supplementary Table 2. Full sequence for bacterial expression plasmid Z503 (pEXPR-T7-cfSGFP2-DEVD-CGRP-G)**

*color coding key:*

cfSGFP2: cysteine-free GFP variant (with N-terminal StrepII tag underlined)

Cleavable linker

haCGRP-Gly: Human alpha CGRP extended with one C-terminal glycine residue

Kanamycin resistance gene

pBR322 origin of replication

*sequence:*

GCTCAGAGGATCGAGATCTGATCCCGGAAATTAAACGACTCACTATAGGGAGAGCCACAACGGTTCCCTCTAGAAATAATTT  
TGTAACTTAAGAAGGAGATATACATATGAGCGCGTAGGAGCCATCCGAGTTGAAAAGGTGCTGTATCCAAGGGCGAAGAGC  
TGTTCACGGCGTAGTACCGATTGGTGAGCTGGACGGCGATGTGAACGCCATAAATTAGTGTGAGCGGGCGAAGGTGAGGGC  
GATGCGACATATGGCAAACTGACCCCTGAAATTATTAGTACCCACCGGTAACGCTGCAGTGCCTGGCGACGCTGGTTACACCCCT  
GACCTACGGGTGCAAAGTTCGCTCGCTACCCCACCATATGAAACAGCATGACTTCTCAAGAGCGCAATGCCGAAGGTTACG  
TGCAAGGAGCGTACGATTTTTCAAAAGATGATGGAATTACAAGACAGTCGCGAAGTGAATTGAGGGCGATACGCTGTTAAAT  
CGCATCGAACTGAAAGGCATCGACTTCAAAGAAGATGTTAACATTCTGGTCACAAGCTGAATACAACACTACACATAACGTT  
ATATATCACAGCAGATAAGGAGAAGATGGTATTAAGGCGAATTCAAGATCCGTCACATTGAGGATGCCGTGTTCAAGT  
CTGATCATTATCAACAGAACACCCCTATTGGAGATGCCAGTGTCTACTGGAGTTCTGACAGCGCGGGCATACGCTGGGTATGGATGAGCT  
AGCAAAGACCTTAATGAGAACCGTGTATGGTCTACTGGAGTTCTGACAGCGCGGGCATACGCTGGGTATGGATGAGCT  
GTATAAGGGTGGCTCAGGTGATGAAGTAGATGCTGTGACACAGCCACCTGTGTCACCCACCCTGGCTGCTGTCGCT  
CGGGTGGCGTGTTTAAAAACAAATTGTGCCAACAAATGTTGGTCAAAAGCGTTGGCTAACAAACGCCAAAGGAAGCTGAGTT  
GGCTGCTGCCACCGCTGAGCAAAACTAGCATAACCCCTGGGCCCTCTAAACGGCTTGTGAGGGTTTTGCTGAAAGGAGGAA  
CTATATCCGGATATCCACAGGACGGAGGTAGCTCTGGCCGTGTCAAATCTCTGATGTTACATTGACAAGATAAAATATAT  
CATCATGAACAAATAAAACTGCTGCTACATAAACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGAAACGTCGAGGCCG  
CGATTAAATTCAACATGGATGCTGATTATATGGGTATAAAATGGGCTCGCATAATGTCGGGCAATCAGGTGCCAACATCTATCG  
CTTGTATGGGAAGCCCGATGCGCCAGAGTGTGTTCTGAAACATGGCAAGGTAGCGTGTGCAATGATGTTACAGATGAGATGGTCA  
GACTAAACTGGCTGACGAAATTATGCCCTTCCGACCATCAAGCATTGTTCTGGTACTCTGGTATGCATGGTTACTCACCAC  
GCGATCCCCGGAAAACAGCATTCCAGGTATTAGAAGAATACCTGATTAGGTGAAATATTGTTGATGCCGTGGCAGTGTCCCT  
GCCCGGTTGCATCGATTCCTGTTGTAATTGCCCTTAAACAGCGATCGCGTATTCGCCCTCGCTCAGGCCAACATCAGGAATGA  
ATAACGGTTGGTGATGCGAGTGATTTGATGACGAGCGTAATGGCTGCCGTGTAACAGCTGGAAAGGAAATGCATAAAACTT  
TTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTCTCACTTGATAACCTTATTTTGACGAGGGGAAATTAAAGGTTG  
TATTGATGTTGGACGAGTCGGAATCGCAGACCGGATACCAGGATCTGCCATCTGGAACCTGCCGTGAGTTCTCCCTCAT  
TACAGAAACGGCTTTCAAAATATGGTATTGATAATCCTGATATGAATAATTGCAGTTCTATTGATGCTGATGAGTTTC  
TAATCAGAATTGGTTAACATTGGGTGTAACATTTCAGATTGGCCCGTCCACTGAGCGTCAGACCCGTAGAAAAGATCAAAGG  
ATCTTCTTGAGATCCTTTCTGCGCGTAATCTGCTGCTGCAAACAAAAAAACCCACCGCTACAGCGGTGGTTGCTGCCGG  
ATCAAGAGCTACCAACTCTTCCGAAAGGTAACTGGCTCAGCAGAGCGCAGATACCAAAACTGTTCTAGTGTAGCCGTAG  
TTAGGCCACCACTTCAAGAACCTGTAGCACCGCCTACATACCTCGCTCGTAATCTGTTACAGTGGCTGCTGCCAGTGGCGA  
TAAGTCGTCTTACCGGGTGGACTCAAGACGATAGTTACCGATAAGCGCAGCGTCGGCTGAACGGGGGTTCTGCAAC  
AGCCCGCTGGAGCGAACGACCTACACGAACTGAGGACCTACAGCGTGAGCTATGAGAAAGGCCACGCTCCGAAGGGAGA  
AAGGGCGACAGGTATCCGTAAGCGCAGGGTCGGAACAGGGAGAGCGCAGGAGGAGCTCCAGGGGAAACGCCCTGGTATCTTTA  
TAGTCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTGGTATGCTGTCAGGGGGCGGAGCCTATGGAAAAACGCCA  
GCAACCGCCGCTTTTACGGTCTGCCCTTCTGACATGTTCTGCTCACATGTTCTTCTGCTTATCCCTGATTCTGTTG  
AACCGTATTACCGCTAGCATGGATCTGGGGACCTTAACGAGAGTAGGAACTGCCAGGCATCAAATAAAACGAAAG  
GCCCGTCTCCGACTGAGCCTTCGTTATGTTGCTGCGGTAACGCTCTCTGAGTAGGACAAATCCGCCGGAGCGGA  
TTGAACGTTGTAAGCAACGGCCGGAGGGTGGCGGGAGACGCCGACATAAAACTGCCAGGCATCAAACAACTAAGCAGAAGGCCA  
TCCTGACGGATGGCCTTTGCGTTTACAAACTCTTCCTGTTAGTTACTTAA

**Supplementary Table 3. DNA and amino acid sequence of cleavable linkers for all bacterial expression plasmids**

Z503 (pEXPR-T7-cfSGFP2-DEVD-CGRP-G)

GGTGGCTCAGGTGATGAAGTAGAT

G G S G D E V D

Z507 (pEXPR-T7-cfSGFP2-DDDDK-CGRP-G)

GGTGGCTCAGGTGACGATGATGACAAG

G G S G D D D D K

Z508 (pEXPR-T7-cfSGFP2-ENLYFQG-CGRP-G)

GGTGGCTCAGGTGAAAACTTGTATTCCAGGGT

G G S G E N L Y F Q G

**Supplementary Table 4. Full sequence of lentiviral plasmid C501 (pLV-hEF1a- mKate-2A-bla)**

*color coding key:*

**hEF1a:** Human elongation factor 1 alpha promoter

**Transgene cassette:** mKate2: Red fluorescent protein

**2A:** Autoproteolytic viral amino acid sequence

**Bla:** Blasticidin resistance gene

**delta\_U3 / 3'LTR:** HIV 3'LTR with deletion in the U3 region

**AmpR:** Ampicillin resistance gene

**pUC origin of replication**

**RSV / 5'LTR:** Rous Sarcoma Virus / HIV 5'LTR hybrid promoter

**Psi:** Lentiviral Psi packaging sequence

**RRE:** Rev response element

**CPPT:** Central polypurine tract

*sequence:*

CTTGCAAGCTAAATGGACCTTCTAGGTCTTGAAGGAGTGG**GAATTGGCTCCGGTGCCCGTCAGTGGCAGAGCGCACATGCCAC**  
**AGCCCCGAGAACGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAACGGTGGCGCGGGGAAACTGGAAAGTGTGCG**  
**TGTACTGGCTCCGCCCTTTCCCAGGGTGGGGAGAACCGTATAAGTGCAGTAGTCGCCGTGAACGTTCTTCGCAACGGG**  
**TTTGGCCAGAACACAGTAAGTGCCTGTGTGGTCCCGCGGGCCTGCCCTTTACGGTTATGGCCCTTGCCTGCCTGAAT**  
**TACTTCCACCTGGCTGCAGTACGTGATTCTGATCCCGAGCTCGGGTGGAAAGTGGTGGAGAGTTCTGAGGCCCTTGCCTTAAG**  
**GAGCCCCCTCGCCCTCGTGTGAGTTGAGGCCTGGCCTGGCGCTGGGGCGCCGCGTGCAGATCTGGTGGCACCTTCGCGCCTGT**  
**CTCGCTGCTTCGATAAGTCTCTAGCCATTAAAATTTTGATGACCTGTCGACGCTTTTTCTGGCAAGATAAGTCTTGAA**  
**TGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTGGGGCGCGGGCGACGGGGCCGTCGCTCCAGCGCACATTCGCG**  
**CGAGGCAGGGGCTCGAGCGCGGCCACCGAGAACATCGGACGGGGTAGTCAGCTCAAGCTGCCGGCTGCTCTGGTGCCTGGCG**  
**CCGCCGTGTATCGCCCCGCCCTGGCGCAAGGTGGCCGGTCCGACCGAGTTGCGTAGCGGAAAGATGGCCGCTCCGGCCC**  
**TGCTGCAGGGAGCTAAAATGGAGGACCGCGCGCTCGGGAGAGCGGGGGTAGTCAACCCACACAAAGGAAAGGGCCTTCGCG**  
**CCTCAGCGTCGCTCATGTGACTCACGGAGTACCGGGCCGTCAGGCACCTCGATTAGTTCTCGAGCTTTGGAGTACGTGCG**  
**TCTTAGGTTGGGGGAGGGTTTATGCGATGGAGTTCCACACTGAGTGGTGGAGACTGAAGTTAGGCGAGCTTGCACACTT**  
**GATGTAATTCTCTGGAAATTGCCCCTTTGAGTTGGATCTGGTCACTTCAGCCTCACAGACAGTGGTCAAAGTTTTTC**  
**TTCCATTCAGGTGCGTGGAGGAATTAGCTGGTACTAATACGACTCACTATAGCTGGCACC**ATGGTGGAGCGAGCTGATTAAGG****  
**AGAACATGCACATGAAGCTGTACATGGAGGGCACCGTGAACAAACACCACCTCAAGTGCACATCGAGGGCGAAGGCAAGGCCAC**  
**GAGGGCACCCAGACCATGAGAACATCAAGGGCGTCAGGGCGGGCTCTCCCTTCGCGCATCTGGCTACAGCTTACATGTA**  
**CGCGAGAAAACCTTCATCAACCACACCAGGGCATCCCCGACTTCTTAAGCAGTCCTCCCGAGGGCTCACATGGGAGAGAG**  
**TCACCACATACGAAGATGGGGCGTGTGACCGCTACCCAGGACACCAGCTCCAGGACGGCTGCCTCATACAACGTCAAGATC**  
**AGAGGGGTGAACTTCCCCTCAACAGGGCTGTGATGCGAGAACAAACACTCGGCTGGAGGGCTCCCGAGACACTGTACCCGC**  
**TGACGGCGGCTTGGAGGGAGAGCCACATGGCCCTGAAGCTCGTGGGGGGGCCACCTGATCTGAAACCTTAAGACCGACATACA**  
**GATCCAAGAAACCGCTAAGAACCTCAAGATGCCCGCTCACTATGGAGCAGGGAGACTGAAAGAACATCAAGGAGGCCACAAA**  
**GAGACATACGTCGAGCAGCACGAGGTGGCTGTGCCAGATACTGCGACCTCCCTAGCAAACACTGGGCACAAACTTAATTCCGCTGA**  
**GGGCCGCGCAGCCTGCTGACCTGCCGACGTGGAGGAAACCCAGGCCA**ATGGCTAAGCCTTGTCTCAAGAAGATCCACCC****  
**TCATTGAAAGAGCAACGGCTACAATCAACAGCATCCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTAGCGACGGC**  
**CGCATCTTCACTGGTGTCAATGTATATCATTTCAGGGGACCTTGTGCAGAACTCGTGGTGGACTGCTGCTGCTGCG**  
**AGCTGGCAACCTGACTTGTATCGTCCGATCGGAATGAGAACAGGGGACATCTGAGGCCCTGCGACGGTGGCAGAGGTGCTTC**  
**TCGATCTGCATCTGGATCAAAGCCATAGTGAAGGACAGTGTGACAGCCGACGCCAGTGGGATTCTGTGAATTGCTGCCCT**  
**GGTTATGTGGGGAGGGATAAGGGACAGGTGATATCCAGCACAGTGGCGGCCCTGACAATCAACCTCTGGATTACAAAATTGT**  
**GAAAGATTGACTGGTATTCTTAACTATGTTGCTCTTTACGCTATGTGGATACGCTGCTTTAATGCCCTTGATCATGCTATTG**  
**TTCCCGTATGGCTTCTATTTCTCTCTGTATAAATCTGGTTGCTGCTCTTTATGAGGAGTGTGGCCCTGTCAGCTCCTTCCGGACTT**  
**GTGGCGTGGTGTGCACTGTGTTGCTGACGCAACCCCCACTGGTGGGCCATTGCCACCTGTCAGCTCCTTCCGGACTTC**  
**GCTTCCCCCTCCCTATTGCCACGGCGAACACTCATGCCGCCCTGCCCTGCCGCTGCTGGACAGGGCTGGCTTGGCAAC**  
**CAATTCCGTGGTGTGCGGGAAAGCTGACGCTCCCTCATGGCTGCTGCCCTGTGTGCCACCTGGATTCTGCGCGGGACGTCC**  
**TCTGCTACGTCCTCGGCCCTCAATCCAGCGGACCTTCCCGCGGCCCTGCTGCCGGCTCTGCCGCTCTCCCGCTTCCGCTTC**  
**CTTCGCCCTCAGACGAGTCGGATCTCCCTTGGGCCCTCCCGCTGAAATTCTGAGATATCCGGTTAGTAATGAGTTGGAA**  
**TTAATTCTGTGGAATGTGTCAGTTAGGTGTGGAAAGTCCCCAGGCTCCCGAGGCAGGCAGAACATGCAAAGCATGCACT**  
**ATTAGTCAGCAACCAGGTGGAAAGTCCCCAGGCTCCCCAGCAGGCAGAACATGCAAAGCATGCACTCAATTAGTCAGCAACC**  
**ATAGTCCGCCCTAACTCCGCCCATCCGCCCTAATCTCCGCCAGTCCGCCATTCTCCGCCCATGGCTGACTAATT**  
**TATTTATGCGAGAGGCCGAGGCCCTGCTGCCCTGAGCTATTCCAGAAGTAGTGTGAGGAGGCTTTGGAGGCCAGGCTAGGCTT**  
**AAAAGCTCCCCCTGTTGACAATTATCATGGCATAGTATATCGGCATAGTATAACGACAAGGTGAGGAACAAACCATGGCCA**



**Supplementary Table 5. Sequence of transgene cassette for C503 (pLV-hEF1a-prepro-CGRP-IRES-mKate2-2A-bla)**

*color coding key:*

prepro-CGRP: human prepro-CGRP alpha

IRES: Internal ribosome entry site

mKate2: Red fluorescent protein

2A: Autoproteolytic viral amino acid sequence

Bla: Blasticidin resistance gene

*sequence:*

```
ATGGGCTTCAAAAGTTCTCCCCCTTCCTGGCTCTCAGCATTTGGCTGTGCAGGCAGGCAGCCTCCATGCAGCACCAATTAG  
GTCGCCCTGGAGAGCAGCCCAGCAGACCCGGCACGCTCAGTGAGGACGAAGCGCGCCTCCTGCTGGCTGCACTGGTGCAAGGACT  
ATGTGCAGATGAAGGCCAGTGAGCTGGAGCAGGAGCAAGAGAGAGAGGGCTCAGAACATTCATTGCCAGAAGAGAGCCTGTGACACT  
GCCACCTGTGTGACTCATGGCTGGCAGGGCTGTGAGCAGATCAGGGGGTGTGGTAAGAACAACTTGTGCCACCAATGTGGG  
TTCAAAGCCTTGGCAGGCCGCAGGGACCTCAAGCCTGAAGCTGGATCCGGCCCTCTCCCTCCCCCCCCCTAACGTTACT  
GGCGAAGCCGCTTGGAAATAAGGCCGGTGTGCGTTGTCTATATGTTATTTCACCATAATTGCCGTCTTGGCAATGTGAGGGC  
CCGGAAACCTGGCCCTGCTTCTTGACGAGCATTCTAGGGCTTCCCTCTCGCCAAGGAATGCAAGGTCTGGTAATGTGCG  
TGAAGGAAGCAGTCCCTGGAAAGCTCTTGAAAGACAAACAACGTCTGTAGCGACCCCTTGCAGGGCAGCGGAACCCCCACCTGGC  
GACAGGTGCCCTGCGGCCAAAAGCCACGTGTATAAGATAACCTGCAAAGGCCGACAACCCAGTGCACGTTGTGAGTTGGAT  
AGTTGTGAAAGAGTCAAATGGCTCTCTCAAGCGTATTCAACAAGGGGCTGAAGGTGCCAGAAGGTACCCATTGTATGGGAT  
CTGATCTGGGGCCTCGGTACACATGCTTACATGTGTTAGTCGAGGTTAAAAAAACGTCTAGGCCCGAACACGGGACGTG  
GTTTCCTTGGAAAACACGATGATAATATGCCACAGGCCACCATGGTGAGCGAGCTGATTAAGGAGAACATGCACATGAAGCTG  
ACATGGAGGGCACCGTGAACAACCACCACTCAAGTGCACATCCGAGGGCGAAGGCAAGCCCTACGGGGCACCCAGACCATGAGA  
ATCAAGGCGGTGAGGGCGCCCTTCCCTTCGCCCTCGACATCCTGGCTACAGCTTACATGTCAGGCAGCAAACCTTCATCAA  
CCACACCCAGGGCATCCCCACTTCTTAAGCAGTCCTCCCCGAGGGCTTCACATGGGAGAGAGTCACCCATACGAAGATGGG  
GGGTGCTGACCGCTACCCAGGACACCAGCCTCCAGGACGGCTGCTCATCTACAACGTCAGAGGGTGAACCTCCATCC  
AACGGCCCTGTGATGCAAGAAAACACTCGGCTGGGAGGCCACCTGATCTGCAACCTTAAGACACATACAGATCCAAGAAACCCGTAAGA  
AGCCGACATGCCCTGAAGCTGTGGGGGGGCCACCTGATCTGCAACCTTAAGACACATACAGATCCAAGAAACCCGTAAGA  
ACCTCAAGATGCCCTGCTACTATGTGGACAGGAGACTGAAAGAATCAAGGAGGCCACAAAGAGACATACTGAGGAGC  
GAGGTGGCTGTGGCAGATACTGCGACCTCCCTAGCAAACCTGGGACAAACTTAATTCCGCTGAGGGCCGCGCAGCCTGCTGAC  
CTGCGCGACGTGGAGGAAACCCAGGCCAATGGCTAACGCTTGTCTCAAGAAGAACATCCACCCATTGAAAGAGCAACGGCTA  
CAATCAACAGCATCCCCATCTCTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTAGCGACGGCGCATCTCACTGGTGCAAT  
GTATATCATTACTGGGGACCTTGTGCAGAACACTGTTGCTGGGACTGCTGCTGCTGCCAGCTGGCAACCTGACTTGTAT  
CGTCGCGATCGGAAATGAGAACAGGGCATCTGAGCCCTCGGGACGGTGCCTGACAGGTGCTTCGATCTGCATCCTGGGATCA  
AAGCCATAGTGAAGGACAGTGATGGACAGCCGACGGCAGTGGGATTGTGAATTGCTGCCCTGGTTATGTGAGGGATAA
```

**Supplementary Table 6. Sequence of transgene cassette for C504 (pLV-hEF1a-myc-RAMP1-IRES-mKate2A-bla)**

*color coding key:*

myc-RAMP: Human receptor-activity modifying protein 1 preceded by the *H. influenza* hemagglutinin signal peptide and the c-myc epitope

IRES: Internal ribosome entry site

mKate2: Red fluorescent protein

2A: Autoproteolytic viral amino acid sequence

Bla: Blasticidin resistance gene

*sequence:*

ATGAAGACCATCCTGGCCTGAGCACCTACATCTGCCTGGTGTGCCGAGCAGAACGCTGATCAGCGAGGAGGACCTGGCCTG  
CCAGGAGGCTAACTACGGTGCCTCCCTCCGGAGCTCTGCCTCACCCAGTTCCAGGTAGACATGGAGGCCGTGGGGAGACTCTGT  
GGTGTGACTGGGGCAGGACCATCAGGAGCTACAGGGAGCTGCCGACTGCACCTGGCACATGGCGAGAACGCTGGGCTGCTTCTGG  
CCCAATGCAGAGGTGGACAGGTTCTTCTGGCAGTGCAATGGCGCTACTTCAGGAGCTGCCCATCTCAGGCAGGGCGTGCAGGGA  
CCCGCCCGCAGCATCCTCATCCCCTCATCGTGGTCCCCATCACGGTGACCCCTGCTGGTACGGCACTGGTGGCTGGCAGAGCA  
AGCGCACTGAGGGCATTGTGTAGGACTGGGATCCGCCCTCTCCCTCCCCCCCCCTAACGTTACTGGCGAACGCCGCTTGAATA  
AGGCCGGTGTGCGTTGTCTATATGTTATTTCCACCATATTGCCGTCTTGGCAATGTGAGGGGCCGGAAACCTGGCCCTGTCT  
TCTTGACGAGCATTCTAGGGGTCTTCCCCTCTGCCAAAGGAATGCAAGGTCTGTGAATGTCGTGAAGGAAGCAGTTCTCTG  
GAAGCTTCTGAAGACAACACGCTGTAGCGACCCCTTGAGGCAGCGAACCCCCACCTGGCAGAGGTGCTCTGGGCCA  
AAAGCCACGTGATAAGATAACACCTGCAAAGGCCACAACCCAGTGCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTC  
GGCTCTCTCAAGCGTATTCAACAAGGGCTGAAGGATGCCAGAAGGTACCCATTGTATGGGATCTGATCTGGGCGTGGTAC  
ACATGCTTACATGTGTTAGTCGAGGTTAAAAAAAGCTTAGGCCCGAACACGGGACGTGGTTTCTTGTGAAAAACACG  
ATGATAATATGCCACAGCCACATGGTGAGCTGATTAAGGAGAACATGCACATGAAGCTGTACATGGAGGGCACCGTGAAC  
AACCACCACTCAAGTGCACATCCGAGGGCGAAGGCAAGCCCTACGAGGGCACCCAGACCATGAGAATCAAGGCCGTGAGGGCG  
CCCTCTCCCTCGCCTCGACATCTGGTACCGCTTACAGCTTACGTACGGCAGCAAACCTTCATCAACACACCCAGGGCATCCCCG  
ACTTCTTAAGCAGTCCTCCCCGAGGGCTTCACATGGGAGAGAGTCACACATACGAAGATGGGGCGTGTGACCGTACCCAG  
GACACCAGCCTCCAGGACGGCTGCCATCTACACGTCAGAGATCAGAGGGTGAACCTCCCATCCAACGGCCGTGATGCA  
GAAAACACTCGGCTGGAGGGCTCCACCGAGACACTGTACCCCGCTGACGGCGGCTGGAGGCAGAGCCGACATGGCCCTGAAGC  
TCGTGGCGGGGGCACCTGATCTGAAACCTTAAGACACATACAGATCAAGAAACCGCTAAGAACCTCAAGATGCCCGCGTC  
TACTATGTGGACAGGGAGACTGGAAAGAATCAAGGAGGCCAACAGAGACATACGTGAGCAGCACGGTGGCTGTGCCAGATA  
CTGCGACCTCCCTAGCAAACACTGGGGCACAAACTTAATTCCGCTGAGGGCCGGCGACGCTGCTGACCTGCGGCCACGTGGAGGAAA  
ACCCAGGCCAATGGCTAAGCCTTGTCTCAAGAAGAACATCCACCCCTCATGGAAAGAGCAACGGCTACAATCAACAGCATCCCCATC  
TCGTGAAGACTACAGCGTCGCCAGCGCAGCTCTCTAGCGACGGCGCATCTTCACTGGTGTCAATGTATATCATTTACTGGGG  
ACCTTGTGCAAGAACTCGTGGTGTGGCACTGCTGCTGCCAGCTGGCAACCTGACTTGTATCGTCGCGATCGGAAATGAGA  
ACAGGGGCATTTGAGCCCTGCCGACGGTGCCAGGGTCTCGATCTGCATCTGGATCAAAGCCATAGTGAAGGACAGT  
GATGGACAGCCGACGGCAGTTGGGATTGCTGAATTGCTGCCCTGGTTATGTGTGGGAGGGATAA

**Supplementary Table 7. Sequence of transgene cassette for C505 (pLV-hEF1a-HA-CALCRL-IRES-EYFP-2A-Hygro)**

*color coding key:*

HA-CALCRL: Human calcitonin receptor-like receptor preceded by the *H. influenza* hemagglutinin signal peptide and the influenza hemagglutinin antigen (HA) sequence

IRES: Internal ribosome entry site

EYFP: Enhanced yellow fluorescent protein

2A: Autoproteolytic viral amino acid sequence

Hygro: Hygromycin resistance gene

*sequence:*

ATGAAGACCATCCTGGCCCTGAGCACCTACATCTCTGCCTGGTTCGCCCTACCCCTACGACGTGCCGTGACGCCGAGAATT  
AGAAGAGAGTCTGAGGACTCAATTCAAGTGGGAGTTACTAGAAATAAATCATGACAGCTCAATATGAATGTTACAAAAGATT  
TGCAAGACCCATTCAACAAGCAGAACGGCGTTACTGCAACAGAACCTGGGATGGATGGCTCTGCTGGAACGATGTTGCAGCAGGA  
ACTGAATCAATGCAGCTCTGCCCTGATTACTTCAAGGACTTTGATCCATCAGAAAAAGTTACAAAGATCTGTGACCAAGATGGAAA  
CTGGTTAGACATCCAGCAAGCAACAGAACATGGACAAATTATACCCAGTGTAACTGTAACACCCACGAGAAAGTGAAGACTGCAC  
TAAATTGTTTACCTGACCATAATTGGACACGGATTGTCTATTGCATCACTGCTTATCTCGCTTGGCATATTCTTTTATTCAAG  
AGCCTAAGTGCCTAAAGGATTACCTACACAAAATCTGTTCTCTCATTTGTTGTAACCTGTTGTAACAATCATTCAACCTCAC  
TGCAGTGGCCAACAACCAGGCCCTAGTAGCCACAAATCCTGTTAGTTGCAAAGTGTCCCAGTTCAATTCTACACTGATGGGCT  
GTAATTACTTTGGATGCTCTGTGAAGGCATTACCTACACACACTCATTGTTGGTGGCGTGTGAGAGAAGCAACATTTAATG  
TGGTATTATTCTGGCTGGGGATTCCACTGATTCTGCTGTATACTGCAATTGCTAGAAGCTTATATTACAATGACAATTG  
CTGGATCAGTCTGATAACCCATCTCCTCTACATTATCCATGCCAATTGTCGCTTACTGGTGAATCTTTTCTGTTAA  
ATATTGTAACGGTTCTCATACCAAGTTAAAGTTACACCCAAGCGGAATCCAATCTGTACATGAAAGCTGTGAGAGCTACTCTT  
ATCTTGGTGCATTGCTTGGATTGAATTGTGCTGATTCCATGGCGACTGAGGAAAGATTGCAAGAGGAGGTATATGACTACAT  
CATGCACATCCTTATGCACCTCCAGGGCTTTGGTGTCTACCATTCTGCTCTTAATGGAGAGGTTCAAGCAATTCTGAGAA  
GAAACTGGAATCAATACAAAATCCAATTGGAAACAGCTTCCAACCTCAGAACGCTTCTGAGTGCCTTACACAGTGTCAACA  
ATCAGTGTGGCCAGGTATAGTCATGACTGCTCTAGTGAACACTTAAATGAAAAGCATCCATGATATTGAAAATGTTCTCTT  
AAAACCAGAAAATTATATAATTGAGACTGGGATCCGCCCTCTCCCTCCCCCCCCCTAACGTTACTGGCGAAGCGCCTGGAA  
TAAGGCCGGTGTGCTTTGTCTATATGTTATTCCACCATATTGCGCTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGT  
CTTCTGACGAGCATTCTAGGGCTTTCCCTCTGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTC  
TGGAAGCTTCTGAAGACAAACGCTGTAGCGACCTTGCAGGCAGCGAACCCCCCACCTGGCGACAGGTGCCTCTGCC  
CAAAAGCCACGTGTATAAGATACACCTGCAAGGGCGACAACCCCCAGTGCACGTTGTGAGTTGGATAGTTGTGAAAGAGTC  
ATGGCTCTCTCAAGCGTATTCAACAAGGGCTGAAGGATGCCAGAAGGTACCCATTGTTATGGGATCTGATCTGGGCTCGGT  
ACACATGCTTACATGTGTTAGTCGAGGTTAAAAAAACGTTAGGCCACGGGACGTGGTTCTTGTGAAAACA  
CGATGATAATATGCCACAGCCACATGGTGAACGCAAGGGCAGGGAGCTGTTACCGGGGTGGTGCCTCATCTGTCGAGCTGGACG  
GCCACGTAAACGCCACAAGTTCAGCGTGTCCGGGAGGGCGAGGGCGATGCCACCTACGCCAAGCTGACCCCTGAAGTTCATCTGC  
ACCACCGGCAAGCTGCCGTGCCCTGGCCACCCCTCGTGAACACCTTCGCCCTACGGCCTGCAGTGCCTGCCGCTACCCGACCA  
CATGAAGCAGCACGACTTCTCAAGTCCGCATGCCGAAGGCTACGTCAGGCCACCATCTCTCAAGGACGACGCCA  
ACAAGACCCGCCGAGGTGAAGTTCAGGGCGACACCCCTGGTGAACGCCATGCCGCTAGGAGGACATGACTTCAAGGAGGACGCC  
AACATCCTGGGCACAAGCTGGAGTACAACACTACACAGCCACAACGTCTATATCATGCCGACAAGCAGAACGGCATCAAGGT  
GAACATTCAAGATCCGCCAACATCGAGGACGGCAGCGTGCAGCTGCCGACCATCACCAGCAGAACACCCCCATGCCGACGCC  
CCGTGCTGCTGCCGACACCAACTACCGTGAAGCTTACAGTCAAGCTGAGCAAAGACCCCAACGAGAACGCCGATCACATGGCCTG  
CTGGAGTTCTGACCGCCCGGGATCACTCTGGCATGGACGAGCTACAAGCAATTGGAGGGCCGCCAGCTGCTGACCTG  
CGGCGACGTGGAGGAAACCCGCCCAATGAAAAGCTGAACCTACCGCGACGCTGTCGAGAAGTTCTGATGAAAAGTTG  
ACAGCGTGTCCGACCTGATGCACTCTGGAGGGCGAAGAACTCGTGTCTTCACTGCTGATGTTAGGAGGGCGTGGATATGCTCTG  
CGGGTAAATAGCTGCGCCGATGGTTCTACAAAGATCGTTATGTTATCGGCACCTTGCACTGGCCCGCTCCGATTCCGAAAGT  
GCTTGACATTGGGAATTCAAGCGAGAGCCTGACCTATTGCACTCTCCGCCGTGCACAGGGTGTACGTTGCAAGACCTGCTGAAA  
CCGAACCTGCCGCTGTTCTGCAAGCCGAGGCCATGGATGCGATCGCTGCCGATCTTAGCCAGACGAGCGGGTCCG  
CCATTGGACCGCAAGGAATGGTCAATACACTACATGGCGTGAATTCTATGCGCAGTGTGATCCCCATGTGTATCACTCTG  
GCAAACGTGATGGACGACACCGTCAGTGCCTGCCGAGGCCATGGATGAGCTGATGCTTGGCCGAGGACTGCCGAAG  
TCCGGCACCTCGTCACGCCGATTCTGGCTCAACAAATGCTCTGACGGACAATGGCCGATAACAGCGGTATTGACTGGAGCGAG  
GGCATGTTGGGGATTCCAATACGAGGTCGCCAACATCTTCTCTGGAGGGCGTGGTGGTTATGGAGCAGCAGACGCC  
CTTCGAGCGGAGGCATCCGGAGCTGCAAGGATGCCGCCGCGCTCCGGCGTATATGCTCCGATTGGCTTGACCAACTATCAGA  
GCTTGGTTGACGGCAATTGATGATGCACTGGGCCGAGGTGATGCCAGCAGCAATGCTCCGATCCGGAGGCCGACTGCGGG  
CGTACACAAATGCCCGCAGAACGCGGCCGCTGGACCGATGGCTGTGAGAAGTACTGCCGATAGTGGAAACCGACGCC  
CACTCGTCCGGATGGGAGATGGGGAGGCTAACTGA

**Supplementary Table 8. Sequence of transgene cassette for C512: pLV-hEF1a-Glo22F-IRES-H2B-Cerulean-2A-puro**

*color coding key:*

Glo22F: Engineered cAMP-responsive luciferase (Promega Corp.)

IRES: Internal ribosome entry site

H2B-Cerulean: DNA binding domain of histone 2B fused to Cerulean

2A: Autoproteolytic viral amino acid sequence

Puro: Puromycin resistance gene

*sequence:*

```

ATGCCTGGCGCAGTAGGCAAGGTGGTGCCTTCATCGAGGCTAAGGTGGACTTGGACACTGGTAAGACACTGGGTGTGAACCA
GCGCGGCCAGCTGTGCGTCCGTGGCCCCATGATCATGAGCGCTACGTTAACAAACCCGAGGCTACAAACGCTCTCATCGACAAGG
ACGGCTGGCTGCAACAGCGGCACATCGCTACTGGGACGAGGACGAGCACTTCTCATCGTGACCGGCTGAAGAGCCTGATCAA
TACAAGGGCTACCAGGTAGCGGCGAGCTGGAGAGCATCCTGCTGCAACACCCCAACATCTTGACGCCGGGTGCCGGCT
GCCGACGAGCATGCCGGAGCTGGCGCGCAGTCGTGCTGAAACACGGTAAACCATGACCGAGAAGGAGATCGGGACT
ATGTGGCCAGCCAGGTTACAACGCCAACAGCTGCGCGTGGTGTAGTGGAGGGCTAAAGGACTGACGGGCAAG
TTGGACGCCCGAACATCGGAGATCTCATTAAGGCCAACAGGGATCCAATTGGGATTCTGGTGTCCAGAGAACGGTATGTA
TGAAAGCTTATTGAGTCATGCCATTCTAAATCTTGAGGTTCTGACGCCGAGCTGGCTGATTCTTTTCAATTATTGAATCTGGAGAAC
TATACAACGATGGAGAACAAATCATGCTCAGGGAGATTGCGCTGATTCTTTTCAATTATTGAATCTGGAGAACGATGAAAATTACT
ATGAAAAGAACGGTAAATCAGAAGTGGAGAGAACATGGTGCAGTAGAAATCGCTCGATGCTCGCAGGAGACTTGGAGAGCT
TGCCCTGGTAACTAACAAACCTCGACGACTTCTGCCACGCCATTGGGACTGTCAAATGTTAGCAATGGATGTGCAAGCATTG
AAAGGCTTCTGGGACCTTGCATGGAATTATGAAAGAACATCGCTACCTATGAAAGAACAGTTAGTGTGCCCTGTATGGAACGAA
ATGGATATTGTAGCCAAAACATTAAGAACGGCCAGCGCATTCTACCCACTCGAACGACATATCGAGGTGGACATTACCTACGCCAGTACT
TCCGAGATGAGCGTTCGGCTGGCAGAACGCTATGAAAGCCTATGGCTGAATACAAACCATGGATCGTGGTGTGCGAGAACATAGC
TTGCAGTTCTCATGCCGTGTTGGGCTGCCCTGTCATCGGTGTGGCTGTGGCCCCAGCTAACGACATCTACAACGAGCGAGCT
GCTGAACAGCATGGGCATGCCAGCCCACCGCTGTATTCTGAGCAAGAACGGACTACCAGGGCTTCAAAGCATGTACACCTCGTACTCCAT
TACCGATCATACAAAGATCATCATGGATAGCAAGACCGACTACCAGGGCTTCAAAGCATGTACACCTCGTACTCCAT
TTGCCACCCGGCTTCAACGAGTACGACTCGTCCCCGAGAGCTTCGACCGGGACAAACCATGCCCTGATCATGAACAGTAGTGG
CAGTACCGGATTGCCAACGGCGTAGCCCTACCGCACCGCACCCTGTCGATTAGCTAACGACATCTGCCCGCACCCATCTCGGCA
ACCAAGATCATCCCCGACACCGCTATCCTCAGCGTGGTGCCTTCACACGGCTTCCGATGTTACCCACGCTGGCTACTTGATC
TGC GGCTTCTGGGCTGTGCTCATGTACCGCTTCGAGGAGGCTATTCTGCGCAGCTTCAAGACTATAAGATTCAATCTGCCCT
GCTGGTGCCACACTATTAGCTTCTCGCTAACGACTCTCATGACAAGTACGACCTAACGAACTTGACAGAGATGCCAGCG
GCCGGCGCCCTCAGCAAGGAGGTAGGTGAGGCCAACGCTTCCACCTACAGGCATCCGCCAGGGTACGGCTACGGCTGACA
GAAACAACCAGGCCATTCTGATCACTCCAGAACGGGTTAAAGACTGGGATCCGCCCTCTCCCTCCCCCCCCCTAACGTTACTG
GCCGAAGCCGCTTGAATAAGGCCGGTGTGCGTTGTATATGTTATTCCACCATATTGCCGTCTTGGCAATGTGAGGGCC
CGGAAACCTGCCCTGTCTTCTGACGGCATTCTAGGGCTTCTGCCAACAGGAATGCAAGGCTGTTGAATGTCG
GAAGGAAGCAGTTCTCTGGAAAGCTTCTGAGAACAAACAGCTGTAGCAGGCCCTTGCAAGGAGCGAACCCCCCAGCTGGCG
ACAGGTGCTCTCGCGGAAAAGCCACGTGTATAAGAACACCTGCAAAGGCCACACCCAGTGCACGTTGTGAGTTGGATA
GTGTGTTAAAGACTAAATGGCTCTCTCAAGCGTATTCAACAAGGGGCTGAAGGATGCCAGAGGTAACCCATTGTATGGATC
TGATCTGGGCTCTGGTACACATGCTTACATGTTAGTGTGAGGTTAAAAAACGCTAGGCCCCCGAACACGGGAGCTGG
TTTCTCTGAAAAACACGATGATAATATGCCACAGGCCACATGCCAGGCCAGGGCAAGTCTGCCGCCCCGAAAAAGGGCTC
CAAGAAGGCCGGTACTAACGGCGCAGAACAGAACAGGCCAGGGCAAGGCCAGGGCAAGGCCAGGGCAAGGAGACTATTCCATCTATGTTACA
AGGTTCTGAAGGCAGGTCCACCCCTGACACCGCATTCTGCTCAAGGCCATGGCATCATGAAATTCTGTTGTGAAACGACATTTCGAG
CGCATCGCAGGTGAGGCTTCCGCCCTGGCGCATTACAACAAGCGCTCGACCATCACCTCCAGGGAGATCCAGACGCCGTGCGCCT
GCTGCTGCCCTGGGAGTGGCCAAGCACCGCTGTCGAGGGTACTAACGCCATCACCAAGTACACCCAGGCCAGGGATCCTGGG
TACCGGTGCCACCATGGTGAGCAAGGCCAGGGAGCTTCAACGGGCTTCTGGTGGCTGCCCATCTGGTGGCTGGAGCTGGACGGGAGCTAAAC
GGCCACAAGTCAGCGTGTCCGGCAGGGCGAGGGCGATGCCACCTACGCCAGCTGACGTTCTGCCCCGCTACCCGACCCATGAAGCAGC
GCTGCCCTGGCCACCCCTGACGCCACCTAACGAGGAGGCTGAGTGGCTGGAGGAGCTGGACGCCACATGAAGCAGC
ACGACTTCTCAAGTCCGCCATGCCAACGGCTACGTCAGGCCAGCATCTTCTCAAGGAGCACGGCAACTAACAGACCGC
GCCGAGGTGAAGTTCGAGGGCGACACCTGGTGAACCGCAGCTGAAGGGCATCGACTAACGTTCAAGGAGCACGGCAACATCCTGGG
GCACAAGCTGGAGTACAACGCCATCAGCGACAACGCTATATCACCGCCACAAGCAGAACGGCATCAAGGCCAACTTCAAGA
TCCGCCACAACATCGAGGAGCGCAGCGTGCAGCTGCCGACCACTAACGAGAACACCCCCATCGCGACGGCCCGTGTGCTG
CCCGACAACCAACTACCTGAGCACCCAGTCAAGCTGAGCAAAGACCCCAACGAGAACGGCGATCACATGGTCTGCTGGAGTTCTG
GACCGCCGCCGGGATCACTCTCGGCATGGACGGAGCTGTACAAGGAGGGCGAGCTGCTGACCTGCCGGACGCTGGAGGAAA
ACCCCGGGCCATGACCGAGTACAAGGCCACGGTGCCTGCCACCCGGAGACGCTCCCCGGCGTACGCCACCTCGCCGCC
GGCTGCCGACTACCCGCCACGCCACACCGTCGACCCGGACGCCACATGAGCGGGTACCGAGCTGCAAGAACACTTCCCT
CACCGCGCTGGGCTCGACATGCCAGGGTGTGGCTGGAGGAGAGCGTCG

```

AAGCGGGGGCGGTGTTGCCGAGATCGGCCGCATGGCCGAGTTGAGCGGTTCCCGCTGGCCGCAGCAACAGATGGAAGGC  
CTCCTGGCGCGCACCGGCCAAGGAGCCCACCGTCGGCGTGTGCCCCGACCACCAAGGGCAAGGGCTGGG  
CAGCGCCGTGCTGCTCCCCGGAGTGGAGGCAGCGGCCGGGTGCCGCTTCCCTGGAGACCTCCGCCCCGCAACCTCC  
CCTTCTACGAGCGGCTCGGCTCACCGTCACCGCCGACGTCGAGGTGCCGAAGGACCGCGCACCTGGTGCATGACCCGCAAGCCCC  
**GGTGCCTGA**